IQVIA and Boehringer Ingelheim collaborate on therapeutic data transformation
IQVIA has announced a strategic, long-term partnership with Boehringer Ingelheim focused on strengthening data capabilities across therapeutic areas. As part…
All articles by Salong Debbarma
Salong Debbarma
-
-
Repertoire and Lilly join hands on autoimmune disease therapies
Repertoire Immune Medicines has collaborated with Eli Lilly and Company to develop tolerising therapies to treat several autoimmune diseases. The…
-
Sensorion announces $71.9m reserved offering to expand gene therapy pipeline
Sensorion has announced a €60m ($71.9m) reserved offering through the issuance of 214,285,714 new ordinary shares at €0.28 per share…
-
FDA grants breakthrough status to Biogen’s litifilimab for CLE
The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to Biogen’s litifilimab (BIIB059) for cutaneous lupus erythematosus…
-
FDA accepts Otsuka’s centanafadine application for ADHD treatment
The US Food and Drug Administration (FDA) has accepted for priority review Otsuka Pharmaceutical’s new drug application (NDA) submitted for…
-
Insilico and Qilu Pharmaceutical sign deal for cardiometabolic therapies
Insilico Medicine has entered a strategic partnership with Qilu Pharmaceutical and its subsidiary Shanghai Qilu Pharmaceutical Research Center on drug…
-
Mirum acquires Bluejay Therapeutics to expand rare liver disease pipeline
Mirum Pharmaceuticals has completed the acquisition of Bluejay Therapeutics, expanding its pipeline in rare and severe liver diseases. Agreed in…
-
FDA to review Eisai’s Leqembi Iqlik sBLA for Alzheimer’s
Eisai and Biogen have announced that the US Food and Drug Administration (FDA) has accepted for review the supplemental biologics…
-
Daiichi Sankyo and AstraZeneca’s Enhertu gains NMPA approval for HER2 GEJ
Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has received approval from China’s National Medical Products Administration (NMPA) for adults with…
-
Johnson & Johnson reports 9.1% increase in sales for Q4 2025
Johnson & Johnson (J&J) has reported a 9.1% increase in sales for Q4 2025, reaching $24.56bn, with net earnings rising…